ClinicalTrials.gg
CompletedNCT02953678Updated Nov 24, 2021Results posted

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

A Phase 2 interventional study of Ruxolitinib and Prednisone or methylprednisolone in Graft-versus-host Disease (GVHD), sponsored by Incyte Corporation. Completed at 38 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ruxolitinib in Graft vs Host Disease — 13 open to participants now, 16 under way, 2 of them phase 3. ruxolitinib · Graft vs Host Disease.

Enrollment
11th of 27
71 · median 54
Started
2016
with 1 other
Phase 2
13 of 27
6 open now
Registered
3rd of 27
by date
Lead sponsor
3 of 27
Incyte Corporation

Among the 27 studies testing ruxolitinib in Graft vs Host Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2016, is one of 13 in phase 2, and was the 3rd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

13 of the 27 studies testing ruxolitinib in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ruxolitinib in Graft vs Host Disease, or all of them as a file.
02

Study summary

The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).

03

Conditions studied

  • Graft-versus-host Disease (GVHD)

Browse trials for

Keywords

  • Graft-versus-host disease (GVHD)
  • acute GVHD
  • steroid-refractory
  • ruxolitinib
  • Janus kinase inhibitor
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have undergone first hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic . Recipients of nonmyeloablative and myeloablative conditioning regimens are eligible.
  • Clinically suspected Grades II to IV acute as per MAGIC guidelines, occurring after allo-HSCT with any conditioning regimen and any anti-GVHD prophylactic program.
  • Subjects with - acute GVHD, defined as any of the following:

    • Subjects with progressive GVHD (ie, increase in stage in any organ system or any new organ involvement) after 3 days of primary treatment with methylprednisolone ≥ 2 mg/kg per day (or equivalent).
    • Subjects with GVHD that has not improved (ie, decrease in stage in at least 1 involved organ system) after 7 days of primary treatment with methylprednisolone ≥ 2 mg/kg per day (or equivalent).
    • Subjects who previously began corticosteroid therapy at a lower dose (at least 1 mg/kg per day methylprednisolone) but develop new GVHD in another organ system.
    • Subjects who cannot tolerate a corticosteroid taper, that is, begin corticosteroids at 2.0 mg/kg per day, demonstrate response, but progress before a 50% decrease from the initial starting dose of corticosteroids is achieved.
  • Evidence of myeloid engraftment (eg, ≥ 0.5 × 10\^9/L for 3 consecutive days if ablative therapy was previously used). Use of growth factor supplementation is allowed.
  • Be willing to avoid pregnancy or fathering children

Exclusion criteria

Exclusion Criteria:

  • Has received more than 1 .
  • Has received more than 1 systemic treatment in addition to for acute .
  • Presence of GVHD overlap syndrome as per NIH guidelines.
  • Subjects who have had a splenectomy.
  • Presence of an active uncontrolled infection. An active uncontrolled infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without signs or symptoms will not be interpreted as an active uncontrolled infection.
  • Known infection.
  • Active virus (HBV) or virus infection that requires treatment or at risk for HBV reactivation. Subjects whose immune status is unknown or uncertain must have results confirming immune status before enrollment.
  • Serum creatinine > 2.0 mg/dL or \< 40 mL/min measured or calculated by Cockcroft-Gault equation.
  • Subjects with evidence of primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed.
  • Unresolved toxicity or complications (other than acute GVHD) due to previous allo-HSCT.
  • Any corticosteroid therapy for indications other than GVHD at doses of methylprednisolone or equivalent > 1 mg/kg per day within 7 days of enrollment.
  • Severe organ dysfunction unrelated to underlying GVHD, including:

    • Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent abnormalities not attributable to GVHD and ongoing organ dysfunction).
    • or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy.
    • Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.
  • Currently breast feeding.
  • Received Janus kinase inhibitor (JAK) therapy after allo-HSCT for any indication. Treatment with a JAK inhibitor before allo-HSCT is permitted.
  • Treatment with any other agent, device, or procedure, within 21 days (or 5 half-lives, whichever is greater) of enrollment. Subjects participating in a GVHD prophylaxis study or conditioning regimen should be discussed with the sponsor's medical monitor before enrollment.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
  • Known allergies, , or intolerance to any of the study medications, , or similar compounds.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Ruxolitinib in combination with corticosteroids

    Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.

    Drug: Ruxolitinib · Drug: Prednisone or methylprednisolone

Interventions

  • Also known as: Jakafi, INCB018424

  • DrugPrednisone or methylprednisolone

    Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) at Day 28

    Defined as the percentage of participants demonstrating a complete response (CR), very good partial response (VGPR), or partial response (PR).

    Time frame: From baseline to Day 28

Secondary outcomes

  1. Overall Response Rate (ORR)

    Defined as the percentage of participants demonstrating a CR, VGPR, or PR.

    Time frame: From baseline to days 14, 56, and 100

  2. Nonrelapse Mortality (NRM)

    Defined as the proportion of subjects who died due to causes other than malignancy relapse.

    Time frame: From baseline to Months 6, 9, 12, and 24

  3. Percentage of Participants With Six-month Duration of Response (DOR)

    Defined as the time from first response until graft-versus-host disease (GVHD) progression or death. DOR was assessed when all participants who were on the study completed the Day 180 visit.

    Time frame: From Baseline up to 6 months

  4. Percentage of Participants With Three-month DOR

    Defined as the time from first response until GVHD progression or death. DOR was assessed when all participants who were on the study completed the Day 84 visit.

    Time frame: From Baseline up to 3 months

  5. Relapse Rate

    Defined as the percentage of participants whose underlying malignancy relapsed.

    Time frame: From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)

  6. Relapse-related Mortality Rate

    Defined as the percentage of participants whose malignancy relapsed and had a fatal outcome.

    Time frame: From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)

  7. Failure-free Survival (FFS)

    Defined as the time from first dose of ruxolitinib to the earliest date that a participant died, had a relapse/progression of the underlying malignancy, required additional therapy for aGVHD, or demonstrated signs or symptoms of chronic graft-versus-host disease (cGVHD).

    Time frame: From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)

  8. Overall Survival (OS)

    Defined as the time from study enrollment (first day of ruxolitinib treatment) to death due to any cause.

    Time frame: From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)

  9. Number of Participants With Treatment-emergent Adverse Events (TEAES), Serious TEAEs, And Grade 3 or Higher TEAEs

    AE was any unfavorable and unintended sign, symptom, or disease temporally associated with use of medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Serious AE was any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization. TEAE was an AE that was reported for the first time, or worsening of a pre-existing event after the first dose of study drug (until 30 days after the last dose of study drug). Severity of AEs was described and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03). Grade 3 and above would constitute a severe, life-threatening, or death event.

    Time frame: From signing the informed consent form up to 30-35 days after the last dose of study treatment (up to 24 months)

07

Results

Posted Aug 20, 2019

Participant flow

This study was conducted at 26 study centers in the United States.

Participant flow — Overall Study
MilestoneRuxolitinib in Combination With Corticosteroids
Started71
Completed0
Not completed71
Withdrew: Adverse event20
Withdrew: Death7
Withdrew: Physician decision23
Withdrew: Progressive disease of gvhd7
Withdrew: Relapse of underlying malignancy3
Withdrew: Withdrawal by participant3
Withdrew: Includes 2 participants who discontinued ruxolitinib treatment because of clinical improvement5
Withdrew: Participants were transferred to commercial product.3

Outcome measures

PrimaryOverall Response Rate (ORR) at Day 28

Defined as the percentage of participants demonstrating a complete response (CR), very good partial response (VGPR), or partial response (PR).

Time frame:
From baseline to Day 28
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) at Day 28
ParticipantsRuxolitinib in Combination With Corticosteroids
Responders - CR19
Responders - VGPR7
Responders - PR13
Statistical analysis
  • Ruxolitinib in Combination With Corticosteroids · Exact method for binomial distributions: 54.9 · 95% CI 42.7 to 66.8
SecondaryOverall Response Rate (ORR)

Defined as the percentage of participants demonstrating a CR, VGPR, or PR.

Time frame:
From baseline to days 14, 56, and 100
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsRuxolitinib in Combination With Corticosteroids
Day 1462.0 (49.7 to 73.2)
Day 5636.6 (25.5 to 48.9)
Day 10032.4 (21.8 to 44.5)
SecondaryNonrelapse Mortality (NRM)

Defined as the proportion of subjects who died due to causes other than malignancy relapse.

Time frame:
From baseline to Months 6, 9, 12, and 24
Reported as:
Number · percentage of participants
Nonrelapse Mortality (NRM)
percentage of participantsRuxolitinib in Combination With Corticosteroids
6 months44.4 (32.5 to 55.7)
9 months48.2 (35.8 to 59.5)
12 months52.9 (39.6 to 64.5)
24 months64.8 (46.0 to 78.5)
SecondaryPercentage of Participants With Six-month Duration of Response (DOR)

Defined as the time from first response until graft-versus-host disease (GVHD) progression or death. DOR was assessed when all participants who were on the study completed the Day 180 visit.

Time frame:
From Baseline up to 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Six-month Duration of Response (DOR)
percentage of participantsRuxolitinib in Combination With Corticosteroids
Percentage of Participants With Six-month Duration of Response (DOR)68.2 (49.6 to 81.2)
SecondaryPercentage of Participants With Three-month DOR

Defined as the time from first response until GVHD progression or death. DOR was assessed when all participants who were on the study completed the Day 84 visit.

Time frame:
From Baseline up to 3 months
Reported as:
Number · percentage of participants
Percentage of Participants With Three-month DOR
percentage of participantsRuxolitinib in Combination With Corticosteroids
Percentage of Participants With Three-month DOR84.5 (68.7 to 92.7)
SecondaryRelapse Rate

Defined as the percentage of participants whose underlying malignancy relapsed.

Time frame:
From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)
Reported as:
Number · percentage of participants
Relapse Rate
percentage of participantsRuxolitinib in Combination With Corticosteroids
Relapse Rate7.0 (2.3 to 15.7)
SecondaryRelapse-related Mortality Rate

Defined as the percentage of participants whose malignancy relapsed and had a fatal outcome.

Time frame:
From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)
Reported as:
Number · percentage of participants
Relapse-related Mortality Rate
percentage of participantsRuxolitinib in Combination With Corticosteroids
Relapse-related Mortality Rate5.6 (1.6 to 13.8)
SecondaryFailure-free Survival (FFS)

Defined as the time from first dose of ruxolitinib to the earliest date that a participant died, had a relapse/progression of the underlying malignancy, required additional therapy for aGVHD, or demonstrated signs or symptoms of chronic graft-versus-host disease (cGVHD).

Time frame:
From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)
Reported as:
Median · days
Failure-free Survival (FFS)
daysRuxolitinib in Combination With Corticosteroids
Failure-free Survival (FFS)85.0 (42.0 to 158.0)
SecondaryOverall Survival (OS)

Defined as the time from study enrollment (first day of ruxolitinib treatment) to death due to any cause.

Time frame:
From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)
Reported as:
Median · days
Overall Survival (OS)
daysRuxolitinib in Combination With Corticosteroids
Overall Survival (OS)232.0 (93.0 to 675.0)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAES), Serious TEAEs, And Grade 3 or Higher TEAEs

AE was any unfavorable and unintended sign, symptom, or disease temporally associated with use of medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Serious AE was any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization. TEAE was an AE that was reported for the first time, or worsening of a pre-existing event after the first dose of study drug (until 30 days after the last dose of study drug). Severity of AEs was described and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03). Grade 3 and above would constitute a severe, life-threatening, or death event.

Time frame:
From signing the informed consent form up to 30-35 days after the last dose of study treatment (up to 24 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAES), Serious TEAEs, And Grade 3 or Higher TEAEs
ParticipantsRuxolitinib in Combination With Corticosteroids
TEAEs71
Serious TEAEs59
Grade 3 or Higher TEAEs69

Adverse events

Collected over From signing the informed consent form up to 30-35 days after the last dose of study treatment (up to 24 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib in Combination With Corticosteroids46/71 (64.8%)59/71 (83.1%)69/71 (97.2%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventRuxolitinib in Combination With Corticosteroids
SepsisInfections and infestations9/71
PyrexiaGeneral disorders8/71
Respiratory failureRespiratory, thoracic and mediastinal disorders7/71
Lung infectionInfections and infestations5/71
PneumoniaInfections and infestations5/71
Pneumatosis intestinalisGastrointestinal disorders4/71
BacteraemiaInfections and infestations4/71
Acute kidney injuryRenal and urinary disorders4/71
DiarrhoeaGastrointestinal disorders3/71
Septic shockInfections and infestations3/71
Most frequent other events
Showing 10 of 109
Most frequent other events
EventRuxolitinib in Combination With Corticosteroids
AnaemiaBlood and lymphatic system disorders45/71
HypokalaemiaMetabolism and nutrition disorders34/71
Oedema peripheralGeneral disorders33/71
Platelet count decreasedInvestigations32/71
Neutrophil count decreasedInvestigations27/71
HypomagnesaemiaMetabolism and nutrition disorders24/71
Muscular weaknessMusculoskeletal and connective tissue disorders24/71
DyspnoeaRespiratory, thoracic and mediastinal disorders24/71
NauseaGastrointestinal disorders23/71
FatigueGeneral disorders22/71

Baseline characteristics

The efficacy evaluable population included all participants enrolled in the study.

Age, Continuous
Age, Continuous(years)Ruxolitinib in Combination With Corticosteroids
Mean52.9 ± 14.18
Age, Customized
Age, Customized(Participants)Ruxolitinib in Combination With Corticosteroids
< 65 years58
≥ 65 years13
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib in Combination With Corticosteroids
Female36
Male35
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ruxolitinib in Combination With Corticosteroids
Hispanic or Latino9
Not Hispanic or Latino60
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ruxolitinib in Combination With Corticosteroids
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American3
White66
More than one race0
Unknown or Not Reported0
Height
Height(cm)Ruxolitinib in Combination With Corticosteroids
Mean170.2 ± 10.64
Weight
Weight(kg)Ruxolitinib in Combination With Corticosteroids
Mean78.64 ± 21.651
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Ruxolitinib in Combination With Corticosteroids
Mean26.83 ± 6.193

2 further baseline measures are reported on the registry.

08

Study locations

38 sites
  • Tucson, Arizona 85719, United States
  • Duarte, California 31010, United States
  • La Jolla, California 92903, United States
  • Los Angeles, California 90033, United States
  • Los Angeles, California 90095, United States
  • Stanford, California 94306, United States
  • Denver, Colorado 80218, United States
  • Gainesville, Florida 32610, United States
  • Miami, Florida 33136, United States
  • Tampa, Florida 33612, United States
  • Atlanta, Georgia 30322, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60637, United States
  • Lexington, Kentucky 40536-0293, United States
  • Boston, Massachusetts 02114, United States
  • Grand Rapids, Michigan 49503, United States
  • Minneapolis, Minnesota 55455, United States
  • Saint Louis, Missouri 63110, United States
  • Hackensack, New Jersey 07601, United States
  • New York, New York 10022, United States
  • New York, New York 10065, United States
  • Rochester, New York 14642, United States
  • Charlotte, North Carolina 28204, United States
  • Cincinnati, Ohio 45242, United States
  • Cleveland, Ohio 44195, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Pittsburgh, Pennsylvania 15232, United States
  • Nashville, Tennessee 37203, United States
  • Nashville, Tennessee 37232, United States
  • Dallas, Texas 75246, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84112, United States
  • Seattle, Washington 98109, United States
  • Morgantown, West Virginia 26506, United States
  • Madison, Wisconsin 53705, United States
  • Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14;135(20):1739-1749. doi: 10.1182/blood.2020004823. PubMed 32160294 ↗
  • Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018 Apr;10(5):391-402. doi: 10.2217/imt-2017-0156. Epub 2018 Jan 10. PubMed 29316837 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jan 2018, 13 months.

Results were first posted in Aug 2019, 1 year 6 months after primary completion. A results delay was requested in Jan 2019.

Of 102 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2016
First posted
Nov 3, 2016
StartActual
Dec 30, 2016
Primary completionActual
Jan 31, 2018
CompletionActual
Aug 14, 2019
Results delay requested
Jan 29, 2019
Results first posted
Aug 20, 2019
Last update
Nov 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02953678
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 3, 2016
Start date
Dec 30, 2016
Primary completion
Jan 31, 2018
Completion
Aug 14, 2019
Results posted
Aug 20, 2019
Last update
Nov 24, 2021

Study contacts

Fitzroy Dawkins, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion